April 11, 2018 10:15 AM EDT
Deals

Flush with a $164M raise, Cel­lec­tis ups its bet on CAR-T and gene edit­ing pro­grams

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. claims place­bo-con­trolled vac­cine tri­als are 'rad­i­cal de­par­ture' from past. Ex­perts dis­agree

HHS launch­es $500M uni­ver­sal vac­cine plat­form as RFK Jr. shakes up US vac­cine pol­i­cy

US drug­mak­ers in­creas­ing­ly look abroad for clin­i­cal tri­als as con­fi­dence in FDA wa­vers

Lil­ly CEO Ricks urges Trump to drop drug tar­iff plan

Mod­er­na, fac­ing rev­enue miss­es and po­lit­i­cal head­winds, dis­ap­points Wall Street

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times